Skip to main content
SpringerLink
Log in

Evolving Thrombolytics: from Alteplase to Tenecteplase

  • Review
  • Published:
Neurotherapeutics

Abstract

Alteplase has been the primary thrombolytic used in the treatment of acute ischemic stroke since thrombolysis was first established as an effective treatment of acute ischemic stroke in 1995. Tenecteplase, a genetically modified tissue plasminogen activator, has gained attention as an attractive alternative to alteplase given its practical workflow advantages and possible superior efficacy in large vessel recanalization. As more data is analyzed both from randomized trials and non-randomized patient registries, there is mounting support that tenecteplase appears to be at least equally, if not more, safe and potentially more effective than alteplase in the treatment of acute ischemic stroke. Randomized trials investigating tenecteplase in the delayed treatment window and with thrombectomy are ongoing, and their results are eagerly awaited. This paper provides an overview of completed and ongoing randomized trials and nonrandomized studies analyzing tenecteplase in the treatment of acute ischemic stroke. Results reviewed support the safe use of tenecteplase in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.

  2. Lees KR, Bluhmki E. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. 2010;375.

  3. Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–803.

    Article  PubMed  Google Scholar 

  4. Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611–22.

    Article  PubMed  Google Scholar 

  5. Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.

    Article  PubMed  Google Scholar 

  6. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.

    Article  PubMed  Google Scholar 

  7. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31.

    Article  PubMed  Google Scholar 

  8. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91(9):3670–4. https://doi.org/10.1073/pnas.91.9.3670. PMID: 8170967; PMCID: PMC43643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Huang X, Moreton FC, Kalladka D, et al. Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke. 2015;46(12):3543–6. https://doi.org/10.1161/STROKEAHA.115.011290. Epub 2015 Oct 29 PMID: 26514192.

    Article  CAS  PubMed  Google Scholar 

  10. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000;40(5):508–15. https://doi.org/10.1177/00912700022009125. PMID: 10806604.

    Article  CAS  PubMed  Google Scholar 

  11. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229–45. https://doi.org/10.2165/00003088-200241150-00001. PMID: 12452736.

    Article  CAS  PubMed  Google Scholar 

  12. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716–22. https://doi.org/10.1016/s0140-6736(99)07403-6. PMID: 10475182.

    Article  Google Scholar 

  13. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM, TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36(3):607–12. https://doi.org/10.1161/01.STR.0000154872.73240.e9. Epub 2005 Feb 3. PMID: 15692126.

    Article  CAS  PubMed  Google Scholar 

  14. Coutts SB, Dubuc V, Mandzia J, TEMPO-1 Investigators, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46(3):769–74. https://doi.org/10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12 PMID: 25677596.

    Article  CAS  PubMed  Google Scholar 

  15. Campbell BCV, Mitchell PJ, Churilov L, EXTEND-IA TNK Part 2 investigators, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA. 2020;323(13):1257–65. https://doi.org/10.1001/jama.2020.1511. Erratum. In: JAMA. 2022 Mar 8;327(10):985. PMID: 32078683; PMCID: PMC7139271.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cheng X, Hong L, Zhang J, et al. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection. Presented at the 2022 International Stroke Conference; 2022; New Orleans.

  17. Haley EC Jr, Thompson JL, Grotta JC, Tenecteplase in Stroke Investigators, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707–11. https://doi.org/10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25. PMID: 20185783; PMCID: PMC2860601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study. Stroke Vasc Neurol. 2022;7(1):47–53. https://doi.org/10.1136/svn-2021-000978. Epub 2021 Aug 24. PMID: 34429364; PMCID: PMC8899644.

    Article  PubMed  Google Scholar 

  19. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099–107. https://doi.org/10.1056/NEJMoa1109842. PMID: 22435369.

    Article  CAS  PubMed  Google Scholar 

  20. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368–76. https://doi.org/10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26 PMID: 25726502.

    Article  CAS  PubMed  Google Scholar 

  21. Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781–8. https://doi.org/10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2 PMID: 28780236.

    Article  CAS  PubMed  Google Scholar 

  22. Campbell BCV, Mitchell PJ, Churilov L, EXTEND-IA TNK Investigators, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–82. https://doi.org/10.1056/NEJMoa1716405. PMID: 29694815.

    Article  CAS  PubMed  Google Scholar 

  23. Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511–9. https://doi.org/10.1016/S1474-4422(22)00124-7. Epub 2022 May 4 PMID: 35525250.

    Article  CAS  PubMed  Google Scholar 

  24. Menon BK, Buck BH, Singh N, AcT Trial Investigators, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161–9. https://doi.org/10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29 PMID: 35779553.

    Article  CAS  PubMed  Google Scholar 

  25. Bivard A, Zhao H, Churilov L, TASTE-A collaborators, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol. 2022;21(6):520–7. https://doi.org/10.1016/S1474-4422(22)00171-5. Epub 2022 May 4 PMID: 35525251.

    Article  CAS  PubMed  Google Scholar 

  26. Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645–54.

    Article  CAS  PubMed  Google Scholar 

  27. NHS Greater Glasgow and Clyde. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2) [Internet]. clinicaltrials.gov; 2018 Mar [cited 2022 Dec 1]. Report No.: NCT02814409. Available from: https://clinicaltrials.gov/ct2/show/NCT02814409.

  28. Wang Y. Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Controlled Phase II Trial [Internet]. clinicaltrials.gov; 2022 Mar [cited 2023 Dec 10]. Report No.: NCT05281549. Available from: https://clinicaltrials.gov/ct2/show/NCT05281549.

  29. Hospital Universitari Vall d’Hebron Research Institute. A Multi-center, Randomized, Open-label Blinded Endpoint (PROBE), Phase III Study, for the comparation of tenecteplase (TNK) versus alteplase, with a 1:1 allocation, before thrombectomy in patients with acute ischemic stroke and large vessel occlusion suspicion in Catalonia (TNK-CAT) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2022 Dec 10]. Report No.: NCT05626972. Available from: https://clinicaltrials.gov/ct2/show/NCT05626972.

  30. Boehringer Ingelheim. A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled parallel group trial to assess efficacy and safety of tenecteplase versus alteplase in Chinese patients with acute ischaemic stroke within 4.5 hours after stroke onset [Internet]. clinicaltrials.gov; 2022 Dec [cited 2022 Dec 10]. Report No.: NCT04915729. Available from: https://clinicaltrials.gov/ct2/show/NCT04915729.

  31. Roaldsen MB, Eltoft A, Wilsgaard T, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2022;S1474442222004847.

  32. Genentech, Inc. A phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS) [Internet]. clinicaltrials.gov; 2022 Dec [cited 2022 Dec 10]. Report No.: NCT03785678. Available from: https://clinicaltrials.gov/ct2/show/NCT03785678.

  33. Campbell B. Extending the time window for tenecteplase by effective reperfusion of peNumbrAL tissue in patients with large vessel occlusion [Internet]. clinicaltrials.gov; 2021 Jun [cited 2022 Dec 1]. Report No.: NCT04454788. Available from: https://clinicaltrials.gov/ct2/show/NCT04454788.

  34. Dong Q. Prospective, multicenter, open, end-point blinded, stratified block randomized, parallel positive controlled clinical trial of tenecteplase in acute ischemic stroke with large vessel occlusion over time window [Internet]. clinicaltrials.gov; 2022 Sep [cited 2022 Dec 1]. Report No.: NCT04516993. Available from: https://clinicaltrials.gov/ct2/show/NCT04516993.

  35. Hill DM. Multicentre, Prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose tenecteplase (TNK-tPA) versus standard of care in minor ischemic stroke with proven acute symptomatic occlusion [Internet]. clinicaltrials.gov; 2022 May [cited 2022 Dec 1]. Report No.: NCT02398656. Available from: https://clinicaltrials.gov/ct2/show/NCT02398656.

  36. Wang Y. A phase 3, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial of recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) for injection versus standard medical treatment for acute ischemic stroke due to large vessel occlusion with perfusion mismatch up to 24 hours of symptom onset [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Dec 1]. Report No.: NCT05141305. Available from: https://clinicaltrials.gov/ct2/show/NCT05141305.

  37. Chen HS. MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a prospective, randomized, blinded assessment of outcome and open label multi-center study [Internet]. clinicaltrials.gov; 2022 Jul [cited 2022 Dec 1]. Report No.: NCT04752631. Available from: https://clinicaltrials.gov/ct2/show/NCT04752631.

  38. University of Melbourne. Extending the time window for tenecteplase by effective RecanalizatioN of bAsilar Artery occLusion in Patients With POSTerior Circulation Stroke (POST-ETERNAL) [Internet]. clinicaltrials.gov; 2022 May [cited 2022 Dec 1]. Report No.: NCT05105633. Available from: https://clinicaltrials.gov/ct2/show/NCT05105633.

  39. Hospital Moinhos de Vento. A phase III, randomized, multi-center clinical trial that will examine whether treatment with intravenous TNK is superior to placebo in patients who suffer a non-large vessel occlusion ischemic stroke within 4.5-12 hours from time last seen well [Internet]. clinicaltrials.gov; 2022 Dec [cited 2022 Dec 10]. Report No.: NCT05199662. Available from: https://clinicaltrials.gov/ct2/show/NCT05199662.

  40. Chen HS. Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK): a prospective, random, pilot study [Internet]. clinicaltrials.gov; 2021 Nov [cited 2022 Dec 1]. Report No.: NCT04202458. Available from: https://clinicaltrials.gov/ct2/show/NCT04202458.

  41. Chen HS. Improving neuroprotective strategy for ischemic stroke with poor recanalization after thrombectomy by intra-arterial TNK (INSIST-TNK): a prospective, single arm, pilot study [Internet]. clinicaltrials.gov; 2022 May [cited 2022 Dec 1]. Report No.: NCT04201964. Available from: https://clinicaltrials.gov/ct2/show/NCT04201964.

  42. University Hospital Inselspital, Berne. Safety and efficacy of intra-arterial tenecteplase for noncomplete reperfusion of intracranial occlusions [Internet]. clinicaltrials.gov; 2022 Nov [cited 2022 Dec 1]. Report No.: NCT05499832. Available from: https://clinicaltrials.gov/ct2/show/NCT05499832.

  43. ProMedica Health System. Adjunctive intra-arterial tenecteplase following mechanical thrombectomy pilot trial [Internet]. clinicaltrials.gov; 2021 Dec [cited 2022 Dec 10]. Report No.: NCT05172934. Available from: https://clinicaltrials.gov/ct2/show/NCT05172934.

  44. Hospital Moinhos de Vento. Randomization to EndoVascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Acute Ischemic Stroke Due to Large Intracranial VEssel OcclusioN Trial - DIRECT thrombectomy vs. intravenous TNK plus thrombectomy [Internet]. clinicaltrials.gov; 2023 Jan [cited 2022 Dec 1]. Report No.: NCT05199194. Available from: https://clinicaltrials.gov/ct2/show/NCT05199194.

  45. Miao Z. Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator rhTNK-tPA) thrombolysis for acute large vessel occlusion after successful mechanical thrombectomy recanalization -- a multicenter, prospective, randomized, open-label, blinded end-point trial (ANGEL-TNK) [Internet]. clinicaltrials.gov; 2022 Nov [cited 2023 Jan 11]. Report No.: NCT05624190. Available from: https://clinicaltrials.gov/ct2/show/NCT05624190.

  46. Qiu Z. Intravenous rhTNK-tPA bridging with endovascular treatment versus endovascular treatment alone for stroke patient with large vessel occlusion: a multicenter, randomized controlled trial [Internet]. clinicaltrials.gov; 2022 Oct [cited 2022 Dec 1]. Report No.: NCT04733742. Available from: https://clinicaltrials.gov/ct2/show/NCT04733742.

  47. Mahawish K, Gommans J, Kleinig T, et al. Switching to tenecteplase for stroke thrombolysis: real-world experience and outcomes in a regional stroke network. Stroke. 2021;52(10):e59–63.

    Article  Google Scholar 

  48. Zhong CS, Beharry J, Salazar D, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke. 2021;52(3):1087–90.

    Article  CAS  PubMed  Google Scholar 

  49. Hall J, Thon JM, Heslin M, et al. Tenecteplase improves door-to-needle time in real-world acute stroke treatment. SVIN. 2021;1(1):e000102.

    Article  Google Scholar 

  50. Warach SJ, Dula AN, Milling TJ, et al. Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice. Stroke. 2022;53(12):3583–93.

    Article  CAS  PubMed  Google Scholar 

  51. Warach S, Ranta A, Kim J, Song S, Wallace A, Beharry J, et al. The Comparative Effectiveness of Routine Tenecteplase Versus Alteplase in Acute Ischaemic Stroke (CERTAIN), an international collaborative observational cohort study: lower rate of symptomatic intracranial haemorrhage with tenecteplase. SSRN Journal [Internet]. 2022 [cited 2023 Jan 16]; Available from: https://www.ssrn.com/abstract=4231226.

  52. Kheiri B, Osman M, Abdalla A, Haykal T, Ahmed S, Hassan M, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018;46(4):440–50.

    Article  CAS  PubMed  Google Scholar 

  53. Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156–62.

    Article  CAS  PubMed  Google Scholar 

  54. Katsanos AH, Safouris A, Sarraj A, Magoufis G, Leker RR, Khatri P, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. Stroke. 2021;52(1):308–12.

    Article  CAS  PubMed  Google Scholar 

  55. Katsanos AH, Psychogios K, Turc G, Sacco S, de Sousa DA, De Marchis GM, et al. Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(3):e224506.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Saver JL, Goyal M, van der Lugt A, HERMES Collaborators, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA. 2016;316:1279–88. https://doi.org/10.1001/jama.2016.13647.

    Article  PubMed  Google Scholar 

  57. Kunz WG, Almekhlafi MA, Menon BK, HERMES Collaborators, et al. Public health and cost benefits of successful reperfusion after thrombectomy for stroke. Stroke. 2020;51:899–907. https://doi.org/10.1161/STROKEAHA.119.027874.

    Article  PubMed  Google Scholar 

  58. Powers WJ, Rabinstein AA, Ackerson T, et al. on behalf of the American Heart Association Stroke Council; Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–418. https://doi.org/10.1161/STR.0000000000000211.

    Article  PubMed  Google Scholar 

  59. Warach SJ, Dula AN, Milling TJ. Tenecteplase thrombolysis for acute ischemic stroke. Stroke. 2020;51(11):3440–51.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Dell Medical School, University of Texas at Austin, 1601 Trinity St., Bldg. B, Stop Z0700, Austin, TX, 78712, USA

    Samantha E. Miller & Steven J. Warach

Authors
  1. Samantha E. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven J. Warach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samantha E. Miller.

Ethics declarations

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miller, S.E., Warach, S.J. Evolving Thrombolytics: from Alteplase to Tenecteplase. Neurotherapeutics 20, 664–678 (2023). https://doi.org/10.1007/s13311-023-01391-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13311-023-01391-3

Keywords

Search

Navigation